Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Homologous recombination deficiency real-time clinical assays, ready or not?
Katherine C. Fuh, Mary M. Mullen, Barbara Blachut, et al.
Gynecologic Oncology (2020) Vol. 159, Iss. 3, pp. 877-886
Closed Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
Natalie Ngoi, David S.P. Tan
ESMO Open (2021) Vol. 6, Iss. 3, pp. 100144-100144
Open Access | Times Cited: 106
RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Amanda J. Compadre, Lillian N. van Biljon, Mark C. Valentine, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 13, pp. 2466-2479
Open Access | Times Cited: 32
How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature
Martina Arcieri, Veronica Tius, Claudia Andreetta, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 14
Biomarkers for Homologous Recombination Deficiency in Cancer
Svenja Wagener‐Ryczek, Sabine Merkelbach‐Bruse, Janna Siemanowski
Journal of Personalized Medicine (2021) Vol. 11, Iss. 7, pp. 612-612
Open Access | Times Cited: 53
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
Panagiotis A. Konstantinopoulos, Alexandre André Balieiro Anastácio da Costa, D. Gulhan, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 52
The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis
Ana Luiza Drumond‐Bock, Magdalena Bieniasz
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 47
Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors
Lola Paulet, Alexis Trécourt, Alexandra Léary, et al.
European Journal of Cancer (2022) Vol. 166, pp. 87-99
Open Access | Times Cited: 35
Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer
Ana Veneziani, Clare L. Scott, Matthew J. Wakefield, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 16
Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction
Ying‐Cheng Chiang, Po‐Han Lin, Wen‐Fang Cheng
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 33
Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer—An Opportunity for Targeted Therapy
Laura M. Harbin, Holly H. Gallion, Derek B. Allison, et al.
Diagnostics (2022) Vol. 12, Iss. 4, pp. 842-842
Open Access | Times Cited: 25
Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Sanna Pikkusaari, Manuela Tumiati, Anni Virtanen, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 16, pp. 3110-3123
Open Access | Times Cited: 15
Mutations in homologous recombination repair genes in patients with metastatic endometrial cancer: association with clinical characteristics and prognosis
Ling Zhong, Ying Lin, Chun-Xiao Li, et al.
Journal of Gynecologic Oncology (2025) Vol. 36
Open Access
Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics
Andréa Witz, Julie Dardare, Margaux Betz, et al.
Biomarker Research (2025) Vol. 13, Iss. 1
Open Access
Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review
Ying-Wen Wang, Isaac Allen, Gabriel Funingana, et al.
BJC Reports (2025) Vol. 3, Iss. 1
Open Access
PARP Inhibitors in Pancreatic Cancer
Timothy J. Brown, Kim A. Reiss
The Cancer Journal (2021) Vol. 27, Iss. 6, pp. 465-475
Open Access | Times Cited: 32
Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts
Federica Guffanti, M.F. Alvisi, Alessia Anastasia, et al.
British Journal of Cancer (2021) Vol. 126, Iss. 1, pp. 120-128
Open Access | Times Cited: 31
Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
Rowan Miller, Osnat Elyashiv, Karim El-Shakankery, et al.
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 1105-1117
Open Access | Times Cited: 20
Integrative Genomic Tests in Clinical Oncology
Evgeny N. Imyanitov, Anna P. Sokolenko
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13129-13129
Open Access | Times Cited: 19
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer
Vijayalaxmi Gupta, Jeff Hirst, Shariska Petersen, et al.
Gynecologic Oncology (2021) Vol. 162, Iss. 1, pp. 163-172
Open Access | Times Cited: 25
Artificial intelligence-based image analysis can predict outcome in high-grade serous carcinoma via histology alone
Anna Laury, Sami Blom, Tuomas Ropponen, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 25
Direct prediction of Homologous Recombination Deficiency from routine histology in ten different tumor types with attention-based Multiple Instance Learning: a development and validation study
Chiara Maria Lavinia Loeffler, Omar S.M. El Nahhas, Hannah Sophie Muti, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 9
Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group
Nadja Stiegeler, Dale W. Garsed, George Au‐Yeung, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches
Federica Guffanti, Ilaria Mengoli, Giovanna Damia
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Prediction of homologous recombination deficiency from routine histology with attention-based multiple instance learning in nine different tumor types
Chiara Maria Lavinia Loeffler, Omar S.M. El Nahhas, Hannah Sophie Muti, et al.
BMC Biology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Breast cancer and its therapeutic targets: A comprehensive review
Ayushi Singh, Rakhi Mishra, Avijit Mazumder
Chemical Biology & Drug Design (2023) Vol. 103, Iss. 1
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top